As detailed in Table S2, the concordance rate of p53 IHC and TP53 mutational analysis lay between 60% to 81.5%, which was highest when using >80% and >85% of tumor cells as criteria, suggesting TP53 mutational analysis could be utilized in helping p53 IHC define the right cutoff score of aberrant positive staining in clinical practice. This evidence concerns the gene TP53 and neoplasm.